Navigation Links
Neuroimaging provides insights into new treatment options for Alzheimer's disease
Date:11/10/2009

Amsterdam, November 10, 2009 With about 35 million people around the world suffering from Alzheimer's disease (AD) by the year 2010 and an expectation that these numbers will double every twenty years with approximately 115 million cases by 2050, pressure on healthcare systems worldwide will be intense. In a special issue of the journal Behavioural Neurology, twelve contributions from an international group of researchers discuss imaging techniques that may contribute to early diagnosis and advancements in treatment for this devastating disease.

As life expectancy increases across the globe, the incidence of AD rises dramatically. Currently, AD care costs US Medicare and Medicaid and businesses over $148 billion dollars per year. With an aging population, these costs could potentially triple by 2050. With the prevalence of AD doubling with every decade of life after age 75, merely delaying the onset of AD by five years would produce a 50% decrease in the prevalence of disease.

According to Guest Editor Adam S. Fleisher, M.D., M.A.S., Associate Director of Brain Imaging at the Banner Alzheimer's Institute, "To effectively target prevention therapies at the pre-clinical stage of the disease, we must develop biomarkers which accurately predict future dementia. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) offer great promise as biomarkers for identifying underlying structural, functional and disease specific pathology in AD, MCI and related disease processes."

In this volume, imaging experts present both reviews of the latest developments in this field as well as original work, supporting the conviction that neuroimaging will be of crucial importance in tackling this globally pervasive disease.


'/>"/>

Contact: Esther Mateike
e.mateike@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Page: 1

Related medicine news :

1. New neuroimaging study identifies brain signature for cigarette cravings
2. Researchers use neuroimaging to study ESP
3. Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain
4. Alzheimers Disease Neuroimaging Initiative announces completion of genome-wide analysis
5. Neuroimaging suggests that truthfulness requires no act of will for honest people
6. Study provides hope that some transplant patients could live free of antirejection drugs
7. Study provides hope that some transplant patients could live free of anti-rejection drugs
8. USAID Provides Additional Wildfire Assistance to Greece
9. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
10. New knock-out gene model provides molecular clues to breast cancer
11. PreMD Provides Update on 510(k) Application for PREVU(x) POC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... , ... December 08, 2016 , ... With the increasing ... the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the ... the dental implant and prosthetic market in the U.S. is projected to reach $6.4 ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... Bodycad announced it has been awarded ... reproducibility and speed for 3D constructs via MRI ... orthopaedic applications. These patents are critical to the ... based on each patient,s distinct anatomy. ... the world,s first suite of orthopaedic CAD/CAM software. ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: